ReportGem ReportGem

U.S. COMPANY FILING

NOVO NORDISK A S — Form 6-K filed 2026-07-31

Filed: 2026-07-31Company: NOVO NORDISK A STicker: NVOExchange: NYSEForm: 6-KReport period: 2026-07-31SEC accession: 0001171843-26-005109Event: riskMateriality: 8

Filing text preview

Novo Nordisk announced top-line results from the ZEUS phase 3 cardiovascular outcomes trial. Ziltivekimab showed expected biological effect but did not reduce MACE risk (HR 0.99) in patients with ASCVD, CKD, and inflammation. Safety was similar to placebo, though serious infections were higher. HERMES and ARTEMIS trials will continue, with readouts expected in H1 2027. The outcome will not impact 2026 operating profit outlook but will result in a non-cash impairment charge in Q3 2026.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-31Super Micro Says Top Management Didn't Know of Diversion Scheme2026-08-20Deoleo Shareholders Review Strategic Alternatives for Olive-Oil Business2026-08-20SSE Issues Regulatory Work Letter to Nanmo Bio2026-08-20Autohome Inc. files Form 6-K2026-08-20Sadot Group Inc. Files 8-K: Material Definitive Agreement and Unregistered Sales of Equity Securities2026-08-20WANG ON GROUP: Major transaction regarding disposal of target company and notice of extraordinary general meeting2026-08-206-K2026-08-04 · 6-K